Sign In
Buy CLDX
$33.41
+0.98 (+3.02%)
At Close: Jun 22, 2026
Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
07:46pm, Thursday, 05'th Aug 2021
Celldex (CLDX) delivered earnings and revenue surprises of 15.00% and 207.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
How Good Were Celldex Therapeutics' Latest Clinical Results?
07:04am, Saturday, 24'th Jul 2021
The short answer: They were impressive.
HAMPTON, N.J., July 16, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten pub
Celldex Therapeutics Raises $250M Via Equity To Support Development Of Skin Disease Candidate
06:41am, Wednesday, 14'th Jul 2021
Celldex Therapeutics Inc (NASDAQ: CLDX) has priced an underwritten public offering of around 5.9 million shares at $42.00 per share, representing a discount of about 6% from the last close price of
Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock
08:30pm, Tuesday, 13'th Jul 2021
HAMPTON, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,
Why Celldex Therapeutics Stock Is Jumping Again Today
03:19pm, Tuesday, 13'th Jul 2021
The company announced a public stock offering.
Celldex's Latest Data For Chronic Inducible Urticaria Drug Is Only The Beginning
07:11am, Tuesday, 13'th Jul 2021
Celldex reported positive results from the phase 1b study using CDX-0159 for the treatment of patients with Chronic Inducible Urticaria; Complete response rate of 95%. Expansion opportunity for CDX-01
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
04:01pm, Monday, 12'th Jul 2021
HAMPTON, N.J., July 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to marke
You Should Know About Monday's 2 Big Nasdaq Winners
03:54pm, Monday, 12'th Jul 2021
One's a well-known name, while the other has plenty of potential.
Why Celldex Therapeutics Stock Is Skyrocketing Today
11:09am, Monday, 12'th Jul 2021
Investors liked Celldex's early stage clinical results.
3 Former Penny Stocks To Watch This Week As Earnings Season Kicks Off
10:16am, Monday, 12'th Jul 2021
Why Focus On Penny Stocks? Here Are A Few That Give A Great Answer To That Question.
CLDX Stock Increases Over 30% Pre-Market: Why It Happened
06:39am, Monday, 12'th Jul 2021
The stock price of Celldex Therapeutics, Inc. (NASDAQ: CLDX) increased by over 30% pre-market. This is why it happened.
Celldex Stock Surges As It Touts Early-Stage Skin Disease Study Win For CDX-0159
06:12am, Monday, 12'th Jul 2021
Celldex Therapeutics Inc (NASDAQ: CLDX) got a boost Friday with a data readout from Phase 1b trial of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism
Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021
06:01pm, Friday, 09'th Jul 2021
- 95% complete response rate after single dose of CDX-0159 - - Rapid, profound and durable responses offer patients opportunity for quick, lasting, meaningful relief - - Median duration of response 77
Celldex: Powerful Medicines To Yield Further Upsides
03:15pm, Thursday, 08'th Jul 2021
After Celldex tumbled back in 2018, the stock has now moved beyond recovery.
